Literature DB >> 24163128

NF1 is a critical regulator of muscle development and metabolism.

Kate Sullivan1, Jad El-Hoss, Kate G R Quinlan, Nikita Deo, Fleur Garton, Jane T C Seto, Marie Gdalevitch, Nigel Turner, Gregory J Cooney, Mateusz Kolanczyk, Kathryn N North, David G Little, Aaron Schindeler.   

Abstract

There is emerging evidence for reduced muscle function in children with neurofibromatosis type 1 (NF1). We have examined three murine models featuring NF1 deficiency in muscle to study the effect on muscle function as well as any underlying pathophysiology. The Nf1(+/-) mouse exhibited no differences in overall weight, lean tissue mass, fiber size, muscle weakness as measured by grip strength or muscle atrophy-recovery with limb disuse, although this model lacks many other characteristic features of the human disease. Next, muscle-specific knockout mice (Nf1muscle(-/-)) were generated and they exhibited a failure to thrive leading to neonatal lethality. Intramyocellular lipid accumulations were observed by electron microscopy and Oil Red O staining. More mature muscle specimens lacking Nf1 expression taken from the limb-specific Nf1Prx1(-/-) conditional knockout line showed a 10-fold increase in muscle triglyceride content. Enzyme assays revealed a significant increase in the activities of oxidative metabolism enzymes in the Nf1Prx1(-/-) mice. Western analyses showed increases in the expression of fatty acid synthase and the hormone leptin, as well as decreased expression of a number of fatty acid transporters in this mouse line. These data support the hypothesis that NF1 is essential for normal muscle function and survival and are the first to suggest a direct link between NF1 and mitochondrial fatty acid metabolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24163128      PMCID: PMC3954124          DOI: 10.1093/hmg/ddt515

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

1.  Double inactivation of NF1 in tibial pseudarthrosis.

Authors:  David A Stevenson; Holly Zhou; Shadi Ashrafi; Ludwine M Messiaen; John C Carey; Jacques L D'Astous; Stephen D Santora; David H Viskochil
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

2.  Decreased bone mineral density in patients with neurofibromatosis 1.

Authors:  Marga Lammert; Martin Kappler; Victor-Felix Mautner; Kurt Lammert; Stephan Störkel; Jan M Friedman; Derek Atkins
Journal:  Osteoporos Int       Date:  2005-06-30       Impact factor: 4.507

3.  Models of tibial fracture healing in normal and Nf1-deficient mice.

Authors:  Aaron Schindeler; Alyson Morse; Lorraine Harry; Craig Godfrey; Kathy Mikulec; Michelle McDonald; Jürg A Gasser; David G Little
Journal:  J Orthop Res       Date:  2008-08       Impact factor: 3.494

4.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

5.  An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance.

Authors:  Daniel G MacArthur; Jane T Seto; Stephen Chan; Kate G R Quinlan; Joanna M Raftery; Nigel Turner; Megan D Nicholson; Anthony J Kee; Edna C Hardeman; Peter W Gunning; Gregory J Cooney; Stewart I Head; Nan Yang; Kathryn N North
Journal:  Hum Mol Genet       Date:  2008-01-04       Impact factor: 6.150

6.  Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency.

Authors:  A Aeby; Y Sznajer; H Cavé; E Rebuffat; R Van Coster; O Rigal; P Van Bogaert
Journal:  J Inherit Metab Dis       Date:  2007-08-20       Impact factor: 4.982

7.  Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster.

Authors:  James Jiayuan Tong; Samuel E Schriner; David McCleary; Brian J Day; Douglas C Wallace
Journal:  Nat Genet       Date:  2007-03-18       Impact factor: 38.330

8.  Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort.

Authors:  Sukhdeep Dulai; Julie Briody; Aaron Schindeler; Kathryn N North; Christopher T Cowell; David G Little
Journal:  J Pediatr Orthop       Date:  2007-06       Impact factor: 2.324

9.  Muscular force is reduced in neurofibromatosis type 1.

Authors:  J F Souza; R L F Passos; A C M Guedes; N A Rezende; L O C Rodrigues
Journal:  J Musculoskelet Neuronal Interact       Date:  2009 Jan-Mar       Impact factor: 2.041

Review 10.  Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).

Authors:  Aaron Schindeler; David G Little
Journal:  Bone       Date:  2007-11-28       Impact factor: 4.398

View more
  14 in total

1.  Genome-wide QTL mapping of nine body composition and bone mineral density traits in pigs.

Authors:  Sophie Rothammer; Prisca V Kremer; Maren Bernau; Ignacio Fernandez-Figares; Jennifer Pfister-Schär; Ivica Medugorac; Armin M Scholz
Journal:  Genet Sel Evol       Date:  2014-10-28       Impact factor: 4.297

2.  Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans.

Authors:  Waylan K Bessler; Farlyn Z Hudson; Hanfang Zhang; Valerie Harris; Yusi Wang; Julie A Mund; Brandon Downing; David A Ingram; Jamie Case; David J Fulton; Brian K Stansfield
Journal:  Free Radic Biol Med       Date:  2016-06-03       Impact factor: 7.376

3.  Update from the 2013 International Neurofibromatosis Conference.

Authors:  Scott R Plotkin; Anne C Albers; Dusica Babovic-Vuksanovic; Jaishri O Blakeley; Xandra O Breakefield; Courtney M Dunn; D Gareth Evans; Michael J Fisher; Jan M Friedman; Marco Giovannini; David H Gutmann; Michel Kalamarides; Andrea I McClatchey; Ludwine Messiaen; Helen Morrison; David B Parkinson; Anat O Stemmer-Rachamimov; Catherine D Van Raamsdonk; Vincent M Riccardi; Tena Rosser; Aaron Schindeler; Miriam J Smith; David A Stevenson; Nicole J Ullrich; Thijs van der Vaart; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette C Bakker; Alison C Lloyd
Journal:  Am J Med Genet A       Date:  2014-09-24       Impact factor: 2.802

Review 4.  RASopathies: unraveling mechanisms with animal models.

Authors:  Granton A Jindal; Yogesh Goyal; Rebecca D Burdine; Katherine A Rauen; Stanislav Y Shvartsman
Journal:  Dis Model Mech       Date:  2015-08-01       Impact factor: 5.758

Review 5.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Authors:  M A Summers; K G Quinlan; J M Payne; D G Little; K N North; A Schindeler
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

6.  Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.

Authors:  Paula Nascimento Almeida; Deuilton do Nascimento Barboza; Eloá Borges Luna; Maria Clara de Macena Correia; Rhayra Braga Dias; Ana Caroline Siquara de Sousa; Maria Eugenia Leite Duarte; Maria Isabel Doria Rossi; Karin Soares Cunha
Journal:  Orphanet J Rare Dis       Date:  2018-06-25       Impact factor: 4.123

7.  Population structure, genetic diversity, and selective signature of Chaka sheep revealed by whole genome sequencing.

Authors:  Jie Cheng; Huangqing Zhao; Ningbo Chen; Xiukai Cao; Quratulain Hanif; Li Pi; Linyong Hu; Buren Chaogetu; Yongzhen Huang; Xianyong Lan; Chuzhao Lei; Hong Chen
Journal:  BMC Genomics       Date:  2020-07-29       Impact factor: 3.969

8.  Early development of infants with neurofibromatosis type 1: a case series.

Authors:  Anna May Kolesnik; Emily Jane Harrison Jones; Shruti Garg; Jonathan Green; Tony Charman; Mark Henry Johnson
Journal:  Mol Autism       Date:  2017-11-23       Impact factor: 7.509

9.  Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1).

Authors:  Emily R Vasiljevski; Peter J Houweling; Thusitha Rupasinghe; Tarneet Kaur; Matthew A Summers; Ute Roessner; David G Little; Aaron Schindeler
Journal:  PLoS One       Date:  2020-08-10       Impact factor: 3.240

10.  Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.

Authors:  Valentina Botero; Bethany A Stanhope; Elizabeth B Brown; Eliza C Grenci; Tamara Boto; Scarlet J Park; Lanikea B King; Keith R Murphy; Kenneth J Colodner; James A Walker; Alex C Keene; William W Ja; Seth M Tomchik
Journal:  Nat Commun       Date:  2021-07-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.